The United States "shares the risk" of research so it will be served first if Sanofi finds a vaccine against Covid-19. They "will get the vaccines first", explained to Bloomberg the director general of the French laboratory, Paul Hudson, because "they invested to try to protect their population". An advance that will be a few days or weeks on the rest of the world, he said.

Sanofi, one of the world's leading vaccine specialists, launched the race against the new coronavirus in mid-February, with the announcement of a cooperation agreement with the Authority for Advanced Research and Development in the biomedical field (Barda), which depends on the United States Department of Health.

>> Read also: "The Covid-19 pushes France to relocate its pharmaceutical industry"

Collaborations with GSK and Translate Bio

Sanofi will use its recombinant DNA technology to "speed up the development of a potential Covid-19 vaccine," he said. To this end, the group has allied with the British GSK, a collaboration whose two laboratories hope to obtain a result by 2021.

In addition, the French laboratory is also collaborating with Translate Bio, an American biotech, which develops drugs based on messenger RNA, with the aim of developing another type of vaccine against Covid-19.

Around the world, more than 100 vaccine projects are currently under study, with ten clinical trials already underway.

With AFP

The summary of the France 24 week invites you to come back to the news that marked the week

I subscribe

Take international news everywhere with you! Download the France 24 app

google-play-badge_FR